Skip to main content
Toggle navigation
Search
Home
Browse by Poster Title
Home
Browse by Poster Title
Browse by Poster Title
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#
Sort by
#
Sort by
Title
A
PII-041
A CASE OF HEPATOTOXICITY DURING COMBINATION AXITINIB AND PEMBROLIZUMAB THERAPY IN A CYP3A4 AND CYP3A5 DUAL POOR METABOLIZER
Favorite
PII-122
A COMPUTATIONAL PLATFORM TO SUPPORT THE DEVELOPMENT OF MRNA-BASED VACCINES AND THERAPEUTICS.
Favorite
PI-022
A CRISPR/CAS9-DERIVED ABCB1/ABCG2 KNOCKOUT PLATFORM FOR SUBSTRATE CHARACTERIZATION.
Favorite
PI-001
A LANDSCAPE SURVEY FOR THE PRESENTATIONS APPROVED FOR SUBCUTANEOUS PROTEIN PRODUCTS.
Favorite
PII-109
A LITERATURE REVIEW OF DRUG-DRUG-DISEASE INTERACTION IN PATIENTS WITH HEPATIC OR RENAL IMPAIRMENT.
Favorite
PI-123
A MECHANISTIC QUANTITATIVE SYSTEMS PHARMACOLOGY FRAMEWORK FOR MODEL-INFORMED TRANSLATIONAL ASSESSMENT OF MESENCHYMAL STEM CELL THERAPY IN LUPUS NEPHRITIS
Favorite
PI-052
A MODELING APPROACH TO EXPEDITE THE DEVELOPMENT OF A NEW LONG-ACTING CONTROLLED-RELEASE MULTIPURPOSE FORMULATION CONTAINING MEDROXYPROGESTRONE ACETATE
Favorite
PII-053
A NOVEL MODELING APPROACH FOR PREDICTING THE TIME COURSE OF ANTI-DRUG ANTIBODIES OF BIOLOGICS: APPLICATION TO AXATILIMAB AS AN EXAMPLE
Favorite
LB-010
A PHARMACOLOGY AND PHYSIOLOGY ENABLED MACHINE LEARNING MODEL FOR PHARMACOKINETICS OF ANTIBODY-BASED THERAPEUTICS
Favorite
PI-053
A PHASE 1 MICROTRACER STUDY EVALUATING THE MASS BALANCE, EXCRETION, AND PHARMACOKINETICS OF [14C]-GBT021601, AN ORAL SICKLE HEMOGLOBIN POLYMERIZATION INHIBITOR, IN HEALTHY PARTICIPANTS.
Favorite
PI-110
A PHASE 1, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF A SINGLE DOSE OF RIMEGEPANT IN CHILDREN (>=6 TO <12 YEARS OF AGE) WITH A HISTORY OF MIGRAINE
Favorite
PII-054
A PHASE 1, OPEN-LABEL STUDY IN HEALTHY MALE SUBJECTS OF THE ABSORPTION, METABOLISM, EXCRETION, AND PHARMACOKINETICS OF SEVASEMTEN
Favorite
PI-054
A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL DESIGN, STUDY TO EVALUATE PHARMACOKINETIC COMPARABILITY OF TWO PF-07940367 FILM-COATED TABLET FORMULATIONS ADMINISTERED AS 150 MG UNDER FASTED CONDITIONS IN HEALTHY PARTICIPANTS
Favorite
E-003
A QUANTITATIVE SYSTEMS PHARMACOLOGY QSP) MODEL FRAMEWORK FOR COMBINED CLINICAL EFFICACY AND HEMATOLOGICAL TOXICITY PRECITIONS FOR ANTIBODY DRUG CONJUGATES.
Favorite
PII-055
A RANDOMIZED, THREE-PERIOD, CROSSOVER STUDY OF SINGLE AND REPEATED DOSES OF ELIGLUSTAT IN HEALTHY PARTICIPANTS, CYP2D6 EXTENSIVE AND POOR METABOLIZERS
Favorite
PI-055
A SEMI-MECHANISTIC PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) MODEL OF ABBV-383 CHARACTERIZING THE INTERPLAY BETWEEN SOLUBLE BCMA (SBMCA) AND FREE AND TOTAL PK.
Favorite
PII-115
A SIMPLE AND SENSITIVE ULTRA-HIGH PERFORMANCE LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY (UHPLC-MS/MS) ASSAY TO QUANTIFY TIZANIDINE AND ITS METABOLITES IN HUMAN PLASMA
Favorite
PII-123
A STUDY ON THE PREVALENCE OF CHRONIC CANNABINOID USE INDUCING HYPEREMESIS SYNDROME
Favorite
PI-026
A STUDY TO EVALUATE RELATIVE BIOAVAILABILITY OF THREE NAPAROFENIB (LXH254) FORMULATIONS IN HEALTHY SUBJECTS
Favorite
PI-011
ABSORPTION OF ELIGLUSTAT VIA THE BUCCAL CAVITY FOLLOWING ORAL ADMINISTRATION OF ELIGLUSTAT SOLUTION IN HEALTHY ADULT PARTICIPANTS.
Favorite
PII-056
ADME PROFILING OF TARGETED ORAL PEPTIDE JNJ-77242113
Favorite
PT-015
ADVANCEMENTS IN PEDIATRIC PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING OF DRUGS IN LACTATION FOR GUIDING NEONATAL EXPOSURE RISK ASSESSMENT
Favorite
PWI-003
ADVANCEMENTS IN PEDIATRIC PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING OF DRUGS IN LACTATION FOR GUIDING NEONATAL EXPOSURE RISK ASSESSMENT
Favorite
OAII-001
AI/ML DERIVED MAGNETIC RESONANCE BIOMARKERS FOR BONE FRAGILITY IN DUCHENNE MUSCULAR DYSTROPHY
Favorite
PT-018
AI/ML DERIVED MAGNETIC RESONANCE BIOMARKERS FOR BONE FRAGILITY IN DUCHENNE MUSCULAR DYSTROPHY
Favorite
PI-056
ALTERNATIVE DOSING GUIDELINES TO IMPROVE OUTCOMES IN MULTIDRUG-RESISTANT TUBERCULOSIS.
Favorite
PII-057
AN AUTOMATED COMPARISON PLATFORM FOR INFORMED DRUG LABELING DECISIONS: WEIGHT-BASED DOSING VS. WEIGHT-BANDED DOSING.
Favorite
PI-124
AN INTEGRATED ANALYSIS OF FOUR TARGETED THORIUM CONJUGATES TO ASSESS THE TH-227 AND RA-223 DISTRIBUTION AND TISSUE-RELATED RADIATION.
Favorite
PII-026
AN INTEGRATED PK/PD MODELING FRAMEWORK OF NONCLINICAL EFFICACY AND CLINICAL HEMATOLOGICAL SAFETY TO INFORM DOSE SELECTION OF ATRI TUVUSERTIB IN COMBINATION WITH NIRAPARIB IN PATIENTS WITH PARPI-RESISTANT OVARIAN CANCER
Favorite
PI-057
AN INVESTIGATION INTO THE DOSE-DEPENDENT FOOD-EFFECT FOR DRUGS.
Favorite
PII-110
AN OVERVIEW OF FOOD EFFECT STUDIES IN PEDIATRIC POPULATION SUBMITTED TO U.S. FOOD AND DRUG ADMINISTRATION (FDA) (2004-2024)
Favorite
PII-042
ANALYSIS OF A CLINICAL PROGRAM TO RETURN CLINICALLY ACTIONABLE PHARMACOGENETIC INFORMATION FROM GERMLINE DNA SEQUENCING DATA GENERATED IN MOLECULAR TUMOR BOARDS: WORKFLOW AND ESTIMATED COSTS
Favorite
PI-094
ANALYZING AND INTEGRATING POSTPARTUM PHYSIOLOGICAL CHANGES IN LACTATING WOMEN.
Favorite
PI-126
APPLICATION OF MACHINE LEARNING TO GUIDE OPTIMAL FORMULATION SELECTION IN EARLY-STAGE DRUG DISCOVERY
Favorite
PI-002
APPLICATION OF VIRTUAL TWIN PBPK MODELS IN OBESE WITH CYP3A4 PHENOTYPING USING ENDOGENOUS BIOMARKER DATA.
Favorite
PII-002
APPLICATIONS AND LIMITATIONS OF 4ΒETA-HYDROXYCHOLESTEROL AS A SENSITIVE ENDOGENOUS BIOMARKER
Favorite
PT-019
APPLYING ARTIFICIAL INTELLIGENCE-BASED DIGITAL TWINS IN TUBERCULOSIS CLINICAL TRIALS
Favorite
OAII-003
APPLYING ARTIFICIAL INTELLIGENCE-BASED DIGITAL TWINS IN TUBERCULOSIS CLINICAL TRIALS
Favorite
PI-116
APPRAISAL OF PHARMACODYNAMIC CLAMP STUDY DESIGN FOR GLP-1 RECEPTOR AGONISTS.
Favorite
PII-058
APPROACHES TO HANDLING MISSING DOSING IN POPULATION PHARMACOKINETIC MODELING DUE TO NON-ADHERENCE
Favorite
PI-042
AREAS OF CLINICAL RELEVANCE AND PHARMACOGENE ACTIONABILITY FOR PATIENTS FROM A PHARMACIST-LED, VIRTUAL PHARMACOGENETICS CONSULTATION CLINIC.
Favorite
PI-027
ASSESSING BASELINE AND LONGITUDINAL CIRCULATING TUMOR DNA WITH PROGRESSION FREE SURVIVAL (PFS) IN BRAF V600E MUTANT (BRAFM) METASTATIC COLORECTAL CANCER (MCRC).
Favorite
LB-017
ASSESSING THE IMPACT OF AGE ON CANNABINOID DISPOSITION
Favorite
PI-009
ASSESSMENT OF KNOWLEDGE AND PERCEPTION OF CAR-T CELL THERAPY AMONG HEALTHCARE PROVIDERS IN SAUDI ARABIA
Favorite
PII-095
ASSESSMENT OF THE IMPACT OF NON-COMPARABLE IN VITRO ALCOHOL DOSE DUMPING RELEASE ON SYSTEMIC EXPOSURE USING PBPK ABSORPTION MODELING FOR TOPIRAMATE EXTENDED-RELEASE CAPSULES.
Favorite
PII-095
ASSESSMENT OF THE IMPACT OF NON-COMPARABLE IN VITRO ALCOHOL DOSE DUMPING RELEASE ON SYSTEMIC EXPOSURE USING PBPK ABSORPTION MODELING FOR TOPIRAMATE EXTENDED-RELEASE CAPSULES.
Favorite
PII-059
ASSESSMET OF SUBCUTANEOUS SITE OF INJECTION ON THE PK OF SOTATERCEPT
Favorite
PII-043
ASSOCIATION BETWEEN CYP2D6 GENOTYPE-INHIBITOR INTERACTIONS AND PAIN-RELATED EMERGENCY DEPARTMENT VISITS IN CYP2D6-OPIOID-TREATED PATIENTS
Favorite
LB-002
ASSOCIATION BETWEEN TREATMENT FOR MULTIPLE SCLEROSIS IN PREGNANCY AND PRECONCPETION PERIODS AND FETAL OUTCOMES - A REAL-WORLD RETROSPECTIVE COHORT STUDY
Favorite
PI-043
ATORVASTATIN AS A CARDIOPROTECTIVE AGENT AGAINST CARFILZOMIB-INDUCED CARDIOTOXICITY IN HUMAN INDUCED PLURIPOTENT STEM CELL-DERIVED CARDIOMYOCYTES.
Favorite
B
PI-108
BALANCING BROADENED ELIGIBILITY CRITERIA AND NECESSARY RESTRICTIONS IN ONCOLOGY CLINICAL STUDIES FOR ORGAN IMPAIRMENT
Favorite
PI-104
BARRIERS AND FACILITATORS IN BRINGING MODEL-INFORMED PRECISION DOSING TO THE PATIENT'S BEDSIDE: A SYSTEMATIC REVIEW
Favorite
LB-011
BIIB091, A NONCOVALENT BRUTON'S TYROSINE KINASE (BTK) INHIBITOR IN DEVELOPMENT FOR TREATMENT OF MULTILE SCLEROSIS (MS): MASS BALANCE, ELIMINATION ROUTE, AND METABOLISM IN HEALTHY MALE PARTICIPANTS.
Favorite
PI-003
BIOMARKER UTILIZATION IN NEUROLOGICAL DRUG PRODUCTS APPROVED BY FDA (2008-2023): A LANDSCAPE ANALYSIS.
Favorite
LB-018
BUILDING AN OAT-MATRIX: PERFORMANCE VERIFICATION OF IVIVE-PBPK MODELS IN THE PREDICTION OF OAT1/OAT3 MEDIATED DRUG-DRUG INTERACTIONS
Favorite
PI-095
BUILDING AN OATP1B-MATRIX: PERFORMANCE VERIFICATION OF IVIVE-PBPK MODELS IN THE PREDICTION OF OATP1B1/1B3 MEDIATED DRUG-DRUG INTERACTIONS
Favorite
C
LB-019
CAN PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING COMPLEMENT THERAPEUTIC DRUG MONITORING FOR DIGOXIN DOSE OPTIMIZATION IN PATIENTS WITH RENAL IMPAIRMENT?
Favorite
LB-022
CAN THE POTENTIAL OF A DRUG TO INHIBIT URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE (UGT) ENZYMES BE PREDICTED? INSIGHTS FROM A RETROSPECTIVE ANALYSIS.
Favorite
LB-022
CAN THE POTENTIAL OF A DRUG TO INHIBIT URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE (UGT) ENZYMES BE PREDICTED? INSIGHTS FROM A RETROSPECTIVE ANALYSIS.
Favorite
PI-059
CASDATIFAN (AB521) PHARMACOKINETICS IS SIMILAR WHEN ADMINISTERED AS CAPSULES OR TABLETS AND IS UNAFFECTED BY FOOD
Favorite
PII-060
CHALLENGES IN PREDICTING PEDIATRIC DRUG EXPOSURE WITH ALLOMETRIC SCALING: IMPLICATIONS FOR OPTIMIZING PEDIATRIC TRIAL DESIGNS
Favorite
PII-016
CHARACTERIZATION AND PHARMACOKINETIC MODELLING OF VANCOMYCIN IN CRITICALLY ILL ICU PATIENTS UNDERGOING CVVHD
Favorite
PI-060
CHARACTERIZING COLISTIN PHARMACOKINETICS FOLLOWING A LOADING DOSE: FIRST DESCRIPTION IN AN AFRICAN COHORT.
Favorite
PII-024
CHARACTERIZING METHADONE:METABOLITE RATIO DURING METHADONE INDUCTION IN PREGNANCY
Favorite
PII-027
CHARACTERIZING NETUPITANT'S FUNCTION AS AN NADK2 INHIBITOR: IMPACT ON CELL VIABILITY AND METABOLISM.
Favorite
PII-011
CHARACTERIZING QTC PROLONGATION RISK FROM CONCOMITANT MEDICATIONS IN PATIENTS WITH BREAST CANCER AMONG PHARMETRICS PLUS.
Favorite
LB-006
CLINICAL AND ETHICAL PERSPECTIVES ON THE EMERGING ROLE OF PHARMACOGENOMIC TESTING AMONG MENTAL HEALTH PROVIDERS: A QUALITATIVE EXAMINATION
Favorite
PII-022
CLINICAL DRUG-DRUG INTERACTION STUDIES INVESTIGATING THE EFFECT OF BAY 2927088 ON P-GP AND BCRP USING DABIGATRAN ETEXILATE AND ROSUVASTATIN
Favorite
PII-061
CLINICAL DRUG-DRUG INTERACTION STUDIES THROUGH CYTOCHROME P450 3A (CYP3A) AND P-GLYCOPROTEIN (P-GP) FOR BAY 2927088 USING ITRACONAZOLE (ITZ), CARBAMAZEPINE (CBZ) AND MIDAZOLAM (MDZ)
Favorite
PI-028
CLINICAL PHARMACOKINETICS AND BIOMARKER ANALYSES OF RC88, A NEW MESOTHELIN-TARGETING ANTIBODY DRUG CONJUGATE, IN PATIENTS WITH ADVANCED SOLID TUMORS
Favorite
PII-107
CLINICAL STUDY TO INVESTIGATE THE EFFECT OF ADMINISTRATION OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS AND AN OPIOID ON VENTILATION.
Favorite
PI-061
CLOFAZIMINE PHARMACOKINETICS FOR MULTIDRUG-RESISTANT TB: IMPLICATION OF NOVEL COMBINATION REGIMENS.
Favorite
PII-028
CLONAL HEMATOPOIESIS AS A PRECISION MEDICINE BIOMARKER FOR PATIENTS WITH CANCER
Favorite
PII-003
COMPLIANCE, USABILITY, RELIABILITY, AND CONSTRUCT VALIDITY OF SELF-ADMINISTERED DIGITAL MEASURES DERIVED FROM MDS-UPDRS PARTS 2 AND 3 IN AN OBSERVATIONAL STUDY TO EVALUATE PARKINSON'S DISEASE (PD) PROGRESSION: INTERIM ANALYSIS.
Favorite
PII-062
COMPREHENSIVE PHARMACOKINETIC ANALYSIS OF ISONIAZID IN A LARGE COHORT OF TUBERCULOSIS PATIENTS: ADVANCED MODELING INCORPORATING EXTENSIVE CLINICAL COVARIATES.
Favorite
PI-012
CONCENTRATION-QT ANALYSIS FOR BAY 2927088 INDICATES NO CLINICALLY RELEVANT QTC INTERVAL PROLONGATION
Favorite
PI-062
CONCENTRATION-QTC ANALYSIS OF PATRITUMAB DERUXTECAN IN PATIENTS WITH HER3-EXPRESSING METASTATIC BREAST CANCER OR METASTATIC OR UNRESECTABLE NON-SMALL CELL LUNG CANCER
Favorite
PI-017
CONCENTRATION-RESPONSE RELATIONSHIP OF MAM01, AN INVESTIGATIONAL MONOCLONAL ANTIBODY TARGETING THE CIRCUMSPOROZOITE PROTEIN (CSP), IN A CONTROLLED HUMAN INFECTION MODEL (CHIM) STUDY.
Favorite
PII-012
CONSIDERATIONS FOR PHASE 1 CLINICAL TRIALS IN ADULT PATIENTS
Favorite
PI-013
CONSIDERATIONS ON HUMAN ADME STUDIES AND PROPOSED DECISION TREE TOWARDS TAILORED STUDY DESIGNS.
Favorite
PWII-005
CONSTRUCTING EXTERNAL CONTROL (EC) ARMS FOR ORGAN IMPAIRMENT (OI) STUDIES: COMPARING STATISTICAL MATCHING AND POOLING METHODS
Favorite
PT-020
CONSTRUCTING EXTERNAL CONTROL (EC) ARMS FOR ORGAN IMPAIRMENT (OI) STUDIES: COMPARING STATISTICAL MATCHING AND POOLING METHODS
Favorite
PII-063
COST EFFECTIVENESS OF INDIVIDUALIZED DOSING FOR A HYPOTHETICAL NEW DRUG IN ATOPIC DERMATITIS: A PHARMACOMETRIC-PHARMACOECONOMIC SIMULATION STUDY.
Favorite
LB-004
COUPLING BIOMARKER KNOWLEDGE WITH THE STRENGTHS OF PHARMACOMETRICS AND MACHINE LEARNING FOR INDIVIDUAL PROGNOSIS IN ONCOLOGY: A PRECISION MEDICINE FRAMEWORK FOR HEALTH CARE PROVIDERS
Favorite
E-006
CXCR4 ANTAGONISM CORRECTS PERIPHERAL NEUTROPENIA IN A MOUSE MODEL OF WHIM SYNDROME.
Favorite
D
PII-044
DEMOGRAPHICS AND UTILIZATION OF MEDICATIONS WITH PHARMACOGENETICS GUIDELINES IN THE TRIAL OF PREMPTIVE PHARMAGOGENETICS IN UNDERSERVED PATIENTS (TOPP UP)
Favorite
PT-002
DETERMINING CRITICAL PHYSIOLOGICAL AND DRUG SPECIFIC PARAMETERS FOR ENHANCING A PHYSIOLOGICALLY-BASED PHARMACOKINETICS MODEL FOR THE FEMALE REPRODUCTIVE TRACT
Favorite
PWI-001
DETERMINING CRITICAL PHYSIOLOGICAL AND DRUG SPECIFIC PARAMETERS FOR ENHANCING A PHYSIOLOGICALLY-BASED PHARMACOKINETICS MODEL FOR THE FEMALE REPRODUCTIVE TRACT
Favorite
PT-011
DEVELOPING A SIMULTANEOUS PLASMA AND CENTRAL NERVOUS SYSTEM POPULATION PHARMACOKINETIC MODEL FOR DOLUTEGRAVIR EXPOSURE
Favorite
PT-023
DEVELOPMENT OF AN ADVANCED PBPK MODEL OF THE RESPIRATORY TRACT TO OPTIMIZE PULMONARY DELIVERY AND DOSING OF MO-OH-NAP TROPOLONE NANO-FORMULATION.
Favorite
PII-096
DEVELOPMENT OF A PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL TO PREDICT PHARMACOKINETICS AND DRUG-DRUG INTERACTIONS FOR REPOTRECTINIB
Favorite
PI-111
DEVELOPMENT OF A QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL TO CHARACTERIZE THE EFFECTS OF INHALED CORTICOSTEROIDS ON PEDIATRIC BONE HEALTH.
Favorite
PII-126
DEVELOPMENT OF A SKIN DRYNESS PREDICTION MODEL BASED ON FACIAL IMAGES USING DEEP LEARNING: A PROSPECTIVE COHORT STUDY.
Favorite
PWII-002
DEVELOPMENT OF ADEFOVIR PBPK MODEL TO SUPPORT PROSPECTIVE EVALUATION OF BIOMARKER-INFORMED OAT1 INHIBITION AND EFFECT OF RENAL IMPAIRMENT
Favorite
PT-016
DEVELOPMENT OF ADEFOVIR PBPK MODEL TO SUPPORT PROSPECTIVE EVALUATION OF BIOMARKER-INFORMED OAT1 INHIBITION AND EFFECT OF RENAL IMPAIRMENT
Favorite
LB-020
DEVELOPMENT OF AN R SHINY APPLICATION TO STREAMLINE DRUG-DRUG INTERACTION SIMULATIONS UTILIZING THE SIMCYP-R PACKAGE.
Favorite
PII-116
DEVELOPMENT OF CHARACTERIZATION OF A TRANSDERMAL DRUG DELIVERY SYSTEM FOR ALZHEIMER'S DRUGS.
Favorite
PI-117
DEVELOPMENT OF POPULATION PHARMACOKINETICS MODEL AND R-SHINY SIMULATION PLATFORM FOR MOXIFLOXACIN IN NON-HUMAN PRIMATES
Favorite
E-004
DEVELOPMENT OF QSP PLATFORM MODEL FOR PREDICTING CLINICAL EFFICACY AND CRS INCIDENCE OF CD3 BISPECIFICS IN STEAP1 PROSTATE CANCER
Favorite
PI-004
DIGITAL HEALTH BIOMARKERS FOR CHARACTERIZING DEPRESSION SEVERITY TRAJECTORIES DURING ANTIDEPRESSANT TREATMENT.
Favorite
PI-063
DISPOSITION OF BEXICASERIN TO ITS MAJOR METABOLITE, N-CARBAMOYL GLUCURONIDE (M20), IS NOT INFLUENCED BY GENETIC POLYMORPHIC METABOLISM
Favorite
PI-044
DISRUPTING THE PD-L1 AND PDS5B INTERACTION BY COMPOUNDS: A PROMISING THERAPEUTIC STRATEGY FOR TRIPLE-NEGATIVE BREAST CANCER.
Favorite
TIP-001
DIVERSITY IN ACTION, CASE STUDIES OF ASTRAZENECA-SPONSORED PHASE-I TRIALS.
Favorite
PII-045
DNA METHYLTRANSFERASE INHIBITORS REDUCE TRIPLE NEGATIVE BREAST CANCER CELL GROWTH THROUGH ENHANCED IMMUNE RESPONSE BY DOWNREGULATION OF ZNF101
Favorite
PII-117
DRUG DEVELOPMENT CONSIDERATIONS FOR DRUG-DRUG INTERACTION STUDIES WITH FLUCONAZOLE AS A SIMULTANEOUS INHIBITOR OF MULTIPLE METABOLIC ENZYMES.
Favorite
PII-064
DRUG-DRUG INTERACTION MODEL DESCRIBES HIGH-DOSE METHOTREXATE PHARMACOKINETICS AFTER GLUCARPIDASE RESCUE
Favorite
PI-064
DRUG-DRUG INTERACTIONS BETWEEN ANDROGEN RECEPTOR SIGNALING INHIBITORS AND DIRECT-ACTING ORAL ANTICOAGULANTS IN PATIENTS WITH PROSTATE CANCER: LIMITED AGREEMENT BETWEEN VARIOUS DRUG-DRUG INTERACTION INFORMATION SOURCES
Favorite
PII-065
DRUG-DRUG INTERACTIONS BETWEEN LETERMOVIR AND TARGETED THERAPIES FOR GRAFT VERSUS HOST DISEASE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: HOW DO DRUG-DRUG INTERACTION CHECKERS COMPARE?
Favorite
PI-118
DRUG-INDUCED ADE PREDICTION MODEL PERFORMANCE DEPENDS ON STATISTICAL MODELS AND STATISTICALLY SIGNIFICANT THRESHOLDS FOR DRUG-INDUCED ADE DATA
Favorite
E
PII-118
EFAVIRENZ ALTERS THE DISPOSITION AND PHARMACODYNAMICS OF TIZANIDINE IN HEALTHY VOLUNTEERS
Favorite
PI-065
EFFECT OF FOOD AND ESOMEPRAZOLE ON THE PHARMACOKINETICS (PK) OF BAY 2927088
Favorite
PI-029
EFFECT OF HEPATIC FUNCTION IMPAIRMENT ON THE PHARMACOKINETICS (PK) OF PARSACLISIB, A SELECTIVE INHIBITOR OF PI3Kδ
Favorite
PI-127
EFFECT OF HYPERTENSION (HTN) AND BLOOD PRESSURE (BP) CONTROL ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH ALZHEIMER'S DISEASE AND RELATED DEMENTIA (ADRD) WITHIN THE STATE OF FLORIDA USING ELECTRONIC HEALTH RECORD (EHR)-BASED DATA.
Favorite
PI-105
EFFECT OF INDUCED HYPOGLYCEMIA ON OXIDATIVE STRESS IN HEALTHY VOLUNTEERS AND THE POTENTIAL APPLICATIONS OF N-ACETYLCYSTEINE
Favorite
PII-105
EFFECT OF P-GLYCOPROTEIN INHIBITION ON TWO TACROLIMUS FORMULATIONS: A RANDOMIZED, 4-SEQUENCE, CROSS-OVER, DRUG-DRUG INTERACTION STUDY
Favorite
PII-029
EFFECT OF RENAL FUNCTION IMPAIRMENT ON THE PHARMACOKINETICS (PK) OF PARSACLISIB, A SELECTIVE INHIBITOR OF PI3Kδ
Favorite
PI-030
EFFECT OF VALEMETOSTAT ON THE PHARMACOKINETICS OF MIDAZOLAM AND DIGOXIN (CYP3A AND P-GP SUBSTRATES): A PHASE 1 DRUG-DRUG INTERACTION STUDY IN PATIENTS WITH REFRACTORY OR RELAPSED NON-HODGKIN LYMPHOMA.
Favorite
PII-017
EFFECTS OF HIV AND OPIOIDS ON CHEMOKINE EXPRESSION IN AN INFECTIOUS MOUSE MODEL
Favorite
PII-111
ESTABLISHING EVIDENCE-BASED, ANTENATAL DOSE RECOMMENDATIONS FOR AMOXICILLIN (WITH AND WITHOUT CLAVULANIC ACID)
Favorite
PI-112
ESTIMATION OF THE AREA UNDER THE CURVE OF MYCOPHENOLIC ACID CONCENTRATION IN CHINESE PEDIATRIC RENAL TRANSPLANT PATIENTS USING LIMITED SAMPLING METHOD.
Favorite
PI-119
EUGLYCEMIC CLAMP STUDY DESIGNS FOR NOVEL INSULINS AND INSULIN BIOSIMILARS.
Favorite
PII-119
EVALUATING AND OPTIMIZING ALLOMETRIC SCALING APPROACHES FOR PREDICTING PEDIATRIC EXPOSURES OF INTRAVENOUSLY ADMINISTERED SMALL MOLECULES AND BIOLOGICS FROM ADULT DATA
Favorite
PII-013
EVALUATING DRUG-DRUG INTERACTIONS WITH ACID-REDUCDING AGENTS: INSIGHTS FROM FDA GUIDANCE AND RECENT APPROVALS
Favorite
PII-004
EVALUATING THE UTILITY OF ENDOGENOUS OCT2 AND MATE1/2-K BIOMARKERS FOR EARLY DDI ASSESSMENT IN ONCOLOGY PHASE 1 STUDIES
Favorite
TIP-002
EVALUATION OF A PHARMACIST-LED PHARMACOGENETICS CONSULTATION SERVICE ON HEALTHCARE COSTS AND OUTCOMES.
Favorite
PII-009
EVALUATION OF ANTIBIOTIC TREATMENTS FOR CELLULITIS: A SYSTEMATIC REVIEW FROM CLINICALTRIALS.GOV
Favorite
OAI-002
EVALUATION OF CAUSAL INFERENCE OF BILE ACIDS ON CARFILZOMIB RELATED CARDIOVASCULAR ADVERSE EVENTS IN PATIENTS WITH MULTIPLE MYELOMA BY MENDELIAN RANDOMIZATION
Favorite
PT-007
EVALUATION OF CAUSAL INFERENCE OF BILE ACIDS ON CARFILZOMIB RELATED CARDIOVASCULAR ADVERSE EVENTS IN PATIENTS WITH MULTIPLE MYELOMA BY MENDELIAN RANDOMIZATION
Favorite
PT-024
EVALUATION OF PRESCRIBER BEHAVIOR IN RESPONSE TO CYP2C19-CLOPIDOGREL BEST PRACTICE ALERTS.
Favorite
PT-025
EVALUATION OF PYRAZINAMIDE PHARMACOKINETICS IN ADOLESCENTS AND ADULTS TO INFORM TUBERCULOSIS DOSING RECOMMENDATIONS.
Favorite
LB-012
EVALUATION OF THE EFFECT OF CYP3A4 AND P-GLYCOPROTEIN INHIBITION BY ITRACONAZOLE OR INDUCTION BY RIFAMPICIN ON THE PHARMACOKINETICS OF ECOPIPAM AND ITS METABOLITES
Favorite
PI-066
EXPLORATORY POPULATION PHARMACOKINETICS AND WEIGHT LOSS MODELING OF HRS9531, A NOVEL DUAL GLP-1/GIP RECEPTOR AGONIST IN CHINESE OBESE ADULTS
Favorite
LB-003
EXPLORING Δ-9-TETRAHYDROCANNABINOL (THC) INDUCED “FEELING HIGH” USING A PHYSIOLOGICALLY BASED PHARMACOKINETIC-PHARMACODYNAMIC MODEL
Favorite
PT-026
EXPLORING THE RELATIONSHIP BETWEEN ANTIDEPRESSANT TREATMENT, NEUROCHEMICALS IN THE BRAIN AND ANXIETY/DEPRESSION SYMPTOMS IN YOUTH
Favorite
PII-067
EXPOSURE RESPONSE (E-R) RELATIONSHIPS OF FEDRATINIB IN PATIENTS WITH INTERMEDIATE-2 TO HIGH-RISK MYELOFIBROSIS WITH OR WITHOUT PRIOR RUXOLITNIB EXPOSURE.
Favorite
PI-067
EXPOSURE-EFFICACY ANALYSIS OF CAMRELIZUMAB PLUS RIVOCERANIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA.
Favorite
PII-068
EXPOSURE-RESPONSE ANALYSES FOR EFFICACY AND SAFETY OF BMS-986365, A DUAL ANDROGEN RECEPTOR LIGAND-DIRECTED DEGRADER AND ANTAGONIST, IN PATIENTS WITH PROGRESSIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Favorite
PI-068
EXPOSURE-RESPONSE ANALYSIS OF MK-5475 IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
Favorite
PII-069
EXTERNAL EVALUATION OF A POPULATION PHARMACOKINETICS MODEL OF CRITICALLY ILL PEDIATRIC PATIENTS RECEIVING MEROPENEM
Favorite
OAII-002
EXTREME GRADIENT BOOSTING COMPARED TO TRADITIONAL MODELING FOR PREDICTING PROGRESSION-FREE AND OVERALL SURVIVAL IN PATIENTS WITH RENAL CELL CARCINOMA
Favorite
PT-003
EXTREME GRADIENT BOOSTING COMPARED TO TRADITIONAL MODELING FOR PREDICTING PROGRESSION-FREE AND OVERALL SURVIVAL IN PATIENTS WITH RENAL CELL CARCINOMA
Favorite
F
PI-069
FIRST IN HUMAN POPULATION PHARMACOKINETIC ANALYSIS OF THE EGFR INHIBITOR WSD0922-FU.
Favorite
PII-070
FIRST-IN-PEDIATRIC DOSE SELECTION OF PATRITUMAB DERUXTECAN USING MODELING AND SIMULATION
Favorite
PT-017
FLUOXETINE RESPONSE ASSOCIATED WITH ENANTIOMER ABUNDANCE IN ADOLESCENTS.
Favorite
PI-045
FREQUENCIES OF CLINICALLY ACTIONABLE POLYMORPHISMS, GENOTYPES, AND PHENOTYPES OF CYP2D6 AND CYP2C19 GENES IN THE CENTRAL INDIAN POPULATION WITH COMMON MENTAL DISORDERS
Favorite
PWI-005
FROM PICU TO NICU: REFINING MATURATION FACTOR FOR MEROPENEM CLEARANCE.
Favorite
PT-012
FROM PICU TO NICU: REFINING MATURATION FACTOR FOR MEROPENEM CLEARANCE.
Favorite
G
LB-007
GENETIC POLYMORPHISMS IN SLC5A2 ARE ASSOCIATED WITH CLINICAL OUTCOMES AND SGLT2I RESPONSE IN HEART FAILURE PATIENTS.
Favorite
PII-112
GENETIC PREDICTORS OF RESPONSE TO RISPERIDONE IN CHILDREN AND ADOLESCENTS: INSIGHTS FROM A PSYCHIATRIC HOSPITAL SERVING RURAL AND UNDERSERVED YOUTH
Favorite
PII-046
GENETIC VARIANTS PREDICTIVE OF FEBRILE NEUTROPENIA DURING INDUCTION I IN PEDIATRIC ACUTE MYELOID LEUKEMIA PATIENTS
Favorite
PI-046
GENOME WIDE ASSOCIATION STUDY OF APPARENT TREATMENT RESISTANT HYPERTENSION (ATRH): INSIGHTS FROM THE ALL OF US RESEARCH PROGRAM.
Favorite
PII-047
GENOME-WIDE ASSOCIATION STUDY IDENTIFIES ASSOCIATIONS WITH METHOTREXATE RESPONSE IN PULMONARY SARCOIDOSIS.
Favorite
PI-047
GENOME-WIDE ASSOCIATION STUDY IDENTIFIES GENETIC VARIANTS ASSOCIATED WITH CARDIOVASCULAR ADVERSE EVENTS IN BREAST CANCER PATIENTS TREATED WITH AROMATASE INHIBITORS: RESULTS FROM THE ALL OF US.
Favorite
PII-048
GENOME-WIDE ASSOCIATION STUDY OF CENTRAL NERVOUS SYSTEM MEDICATION-INDUCED ADVERSE DRUG REACTIONS AMONG A SUBSET OF PARTICIPANTS IN THE NIH ALL OF US RESEARCH PROGRAM
Favorite
LB-008
GENOTYPE-SPECIFIC SAFTEY PROFILES AND PHARMACOKINETICS OF CANNABIDIOL IN HEALTHY SUBJECTS
Favorite
PI-048
GREATER METHOTREXATE EXPOSURE IN HSLCO1B1*14 TRANSGENIC MICE AS THE RESULT OF PHARMACOGENOMIC GUIDED-DOSING NORMALIZES THERAPEUTIC RESPONSE
Favorite
PT-005
GRIN2 IS A POWERFUL TOOL TO IDENTIFY GENOMIC HOT-SPOT LOCI AND ENABLES MULTI-OMICS INTEGRATION.
Favorite
OAI-004
GRIN2 IS A POWERFUL TOOL TO IDENTIFY GENOMIC HOT-SPOT LOCI AND ENABLES MULTI-OMICS INTEGRATION.
Favorite
H
PI-005
HOLISTIC CREDIBILITY ASSESSMENT OF PBPK MODELS FOR TRANSPORTER ENDOGENOUS BIOMARKERS: THE CASE OF COPROPORPHYRIN-I .
Favorite
I
PII-049
IDENTIFYING FUNCTIONAL REGULATORY SNPS THAT REGULATE CYP2C9 EXPRESSION TO OPTIMIZE CYP2C9 BIOMARKER PANELS.
Favorite
PI-049
IMPACT OF CYP2C19 AND CYP3A INHIBITORS ON CLOPIDOGREL CLINICAL EFFECTIVENESS IN CYP2C19 GENOTYPED PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI) IN A REAL-WORLD SETTING.
Favorite
PI-070
IMPACT OF EAST ASIAN ETHNICITY ON PHARMACOKINETICS OF SOTATERCEPT
Favorite
PI-015
IMPACT OF RIFAMPICIN DOSE ON LINEZOLID PHARMACOKINETICS IN TUBERCULOUS MENINGITIS: INSIGHTS FROM THE ALTER TRIAL
Favorite
PI-109
IMPACT OF RISK EVALUATION AND MITIGATION STRATEGY PROGRAMS ON PRODUCT-SPECIFIC GUIDANCES FOR GENERIC DRUG DEVELOPMENT
Favorite
PII-050
IMPACT OF SOCIAL DETERMINANTS OF HEALTH COMPOSITE MEASURES ON OUTCOMES AFTER PCI IN P2Y12 INHIBITOR-TREATED PATIENTS
Favorite
PI-023
INCORPORATING HEPATIC TRANSPORTER ZONATION INTO PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELS: IMPLICATIONS FOR PRAVASTATIN DISPOSITION IN WHITE AND CHINESE POPULATIONS CONSIDERING OATP1B1 PHENOTYPES.
Favorite
PI-050
INFLUENCE OF ALDH2 RS671 POLYMORPHISM ON ANTIBODY TITER AFTER INFLUENZA VACCINATION: A PROSPECTIVE OBSERVATIONAL STUDY
Favorite
PII-031
INFORMATIVE CENSORING BIAS IN DOSE-RESPONSE ANALYSIS OF PROGRESSION-FREE SURVIVAL OF ANTICANCER DRUGS
Favorite
PII-071
INTEGRATED MODEL BASED ANALYSES OF MILVEXIAN PHASE 2 SSP TRIAL DATA SUPPORTS PHASE 3 DOSE SELECTION
Favorite
PWII-003
INTEGRATING BIOMARKERS AND PBPK MODELING TO UNCOVER THE MECHANISM OF A MULTI-TRANSPORTER DDI.
Favorite
PT-004
INTEGRATING BIOMARKERS AND PBPK MODELING TO UNCOVER THE MECHANISM OF A MULTI-TRANSPORTER DDI.
Favorite
PI-018
INTERPLAY BETWEEN HIV AND METHADONE: EFFECTS ON CHEMOKINE DYSREGULATION AND NEUROINFLAMMATION.
Favorite
PII-018
INTESTINAL MICROBIOME AND METABOLOME FLUCTUATIONS IN PATIENTS RECEIVING INTENSE CHEMOTHERAPY FOR AML: RESULTS FROM A PILOT, PROSPECTIVE OBSERVATIONAL STUDY
Favorite
PWI-004
IS ENOXAPARIN DOSING ADEQUATE FOR THROMBOPROPHYLAXIS IN BURN PATIENTS? INSIGHTS FROM REAL-WORLD DATA USING PHARMACOMETRIC MODELING.
Favorite
PT-021
IS ENOXAPARIN DOSING ADEQUATE FOR THROMBOPROPHYLAXIS IN BURN PATIENTS? INSIGHTS FROM REAL-WORLD DATA USING PHARMACOMETRIC MODELING.
Favorite
PII-005
ITPA ACTIVITY TO PREDICT REMISSION WITH METHOTREXATE IN JUVENILE IDIOPATHIC ARTHRITIS
Favorite
L
PT-022
LABELING INFORMATION ON SPECIFIC POPULATIONS FOR NEW MOLECULAR ENTITIES APPROVED BETWEEN 2018 AND 2020
Favorite
PI-071
LEVERAGING AGENTIC WORKFLOWS FOR PK/PD ANALYSIS: ENHANCING CLINICAL PHARMACOLOGY DECISION-MAKING
Favorite
LB-009
LEVERAGING CPIC LEVEL 1A PHARMACOGENOMICS INSIGHTS TO MITIGATE ADVERSE DRUG EVENTS IN OLDER ADULTS: EVIDENCE FROM VIRGINIA ALL-PAYER CLAIMS DATABASE 2016-2020.
Favorite
PI-120
LEVERAGING MACHINE LEARNING FOR HIGH-DIMENSIONAL COVARIATE SCREENING IN ALZHEIMER'S DISEASE PROGRESSION MODELING.
Favorite
PI-120
LEVERAGING MACHINE LEARNING FOR HIGH-DIMENSIONAL COVARIATE SCREENING IN ALZHEIMER'S DISEASE PROGRESSION MODELING.
Favorite
PI-096
LEVERAGING PBPK MODELING TO ENHANCE THE TRANSLATABILITY OF HALF-LIFE EXTENDED MONOCLONAL ANTIBODIES
Favorite
PII-072
LEVERAGING SUPERVISED MACHINE LEARNING TO IDENTIFY PREDICTORS OF ADVERSE EVENTS WITH STIMULANT TREATMENT FROM REAL-WORLD DATA
Favorite
PII-072
LEVERAGING SUPERVISED MACHINE LEARNING TO IDENTIFY PREDICTORS OF ADVERSE EVENTS WITH STIMULANT TREATMENT FROM REAL-WORLD DATA
Favorite
PI-072
LIKELY INHIBITION OF NON-CYP450 PATHWAYS BY BMS-986196 LEADS TO DOUBLING OF EE EXPOSURE.
Favorite
PI-010
LIMITED SAMPLING STRATEGIES FOR NONCOMPARTMENTAL ANALYSES OF ENCORAFENIB PHARMACOKINETIC DATA
Favorite
PI-019
LOW POTENTIAL FOR DRUG INTERACTION BETWEEN LENACAPAVIR AND FENTANYL.
Favorite
M
PII-120
MARFAN: MAXIMIZING ATENOLOL RESPONSE THROUGH FUNCTIONAL ASSESSMENT INVESITGATIONS AMONGST CONNECTIVE TISSUE DISORDERS
Favorite
PII-073
MASS BALANCE, METABOLISM, AND EXCRETION OF [14C] BEXICASERIN IN A SINGLE DOSE RADIOLABEL STUDY IN HEALTHY ADULT MALES.
Favorite
PI-073
MECHANISM-BASED PHARMACOKINETIC-PHARMACODYNAMIC MODELING OF ERYTHROFERRONE: OPTIMIZING RECOMBINANT HUMAN ERYTHROPOIETIN DOSING IN CKD-INDUCED ANEMIA
Favorite
PII-097
MECHANISTIC INSIGHTS INTO CYTOKINE ANTAGONIST-DRUG INTERACTIONS: A PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING APPROACH WITH TOCILIZUMAB AS A CASE STUDY
Favorite
PI-097
MECHANISTIC MODELING OF SPATIAL HETEROGENEITY OF DRUG PENETRATION AND EXPOSURE IN THE HUMAN CENTRAL NERVOUS SYSTEM AND BRAIN TUMORS
Favorite
E-001
MEDICATIONS AND ACUTE HEMOLYSIS IN G6PD-DEFICIENT PATIENTS A REAL-WORLD STUDY. Received February 25, 2024; accepted May 20, 2024. doi:10.1002/cpt.3333
Favorite
PII-127
MEETING CLINICAL TRIAL RECRUITMENT MILESTONES IN ACADEMIC CENTERS: A DATA-DRIVEN VISUAL APPROACH
Favorite
PII-051
METHYLATION PROFILING AND PATHWAY ENRICHMENT ANALYSIS REVEAL EPIGENETIC MECHANISMS IN CARFILZOMIB-RELATED CARDIOTOXICITY IN MULTIPLE MYELOMA PATIENTS .
Favorite
PII-008
MICRORNA REGULATING SEL1L INVOLVED IN THE PATHOGENESIS OF PARKINSON'S DISEASE AND ITS EXPRESSION LEVELS IN PATIENT PLASMA.
Favorite
PT-028
MITIGATING CARDIOTOXICITY OF TRASTUZUMAB AND DOXORUBICIN COMBINATION THERAPY WITH AN INTEGRATED TRANSLATIONAL AND QUANTITATIVE SYSTEMS TOXICOLOGY AND PBPK/PD MODELING APPROACH
Favorite
PWII-004
MITIGATING CARDIOTOXICITY OF TRASTUZUMAB AND DOXORUBICIN COMBINATION THERAPY WITH AN INTEGRATED TRANSLATIONAL AND QUANTITATIVE SYSTEMS TOXICOLOGY AND PBPK/PD MODELING APPROACH
Favorite
PII-074
MODEL INFORMED DOSE OPTIMIZATION OF BALSTILIMAB TO SUPPORT FIXED DOSING ALONE AND IN COMBINATION WITH BOTENSILIMAB IN PATIENTS WITH SOLID TUMORS.
Favorite
PI-032
MODEL INFORMED DOSE OPTIMIZATION OF BOTENSILIMAB ALONE AND IN COMBINATION WITH BALSTILIMAB IN PATIENTS WITH SOLID TUMORS
Favorite
PI-074
MODEL-BASED DRUG DEVELOPMENT CONSIDERATIONS: ZANIDATAMAB IN PATIENTS WITH HER2 EXPRESSING BILIARY TRACT CANCER (BTC)
Favorite
PII-075
MODEL-BASED EVALUATION OF DELANDISTROGENE MOXEPARVOVEC ADENO-ASSOCIATED VIRUS PHARMACOKINETICS AND SAFETY IMPLICATIONS
Favorite
PI-075
MODEL-BASED META-ANALYSIS OF PLACEBO-RESPONSE FOR MONTHLY MIGRAINE DAYS IN MIGRAINE PREVENTION CLINICAL TRIALS FROM LITERATURE
Favorite
PII-076
MODEL-ESTIMATED TISSUE PHARMACOLOGY AS A SURROGATE OF MONOCLONAL ANTIBODY CLINICAL EFFICACY DOSE RESPONSE: CASE STUDY USING DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS.
Favorite
PII-015
MODELING AND SIMULATION ANALYSIS TO SUPPORT DOSE SELECTION FOR MAM01, A NOVEL ANTI-CIRCUMSPOROZOITE PROTEIN MONOCLONAL ANTIBODY, IN UPCOMING TRIALS
Favorite
LB-001
MODELING AND SIMULATION OF POLYAMINE KINETICS DURING ACUTE KIDNEY INJURY
Favorite
PII-032
MOVING TOWARD "FIT-FOR-PURPOSE" QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODELING IN DRUG DEVELOPMENT: CASE EXAMPLES IN ONCOLOGY.
Favorite
PI-033
MULTISTATE MODEL TO INVESTIGATE OVERALL SURVIVAL (OS) FROM COPANLISIB PIVOTAL TRIALS.
Favorite
N
PII-033
NO EFFECT OF IMMUNOGENICITY ON THE PHARMACOKINETICS, EFFICACY, AND SAFETY OF THE NOVEL OLIGONUCLEOTIDE TELOMERASE INHIBITOR IMETELSTAT IN LOWER-RISK MYELODYSPLASTIC SYNDROMES
Favorite
O
PII-098
ON TRANSLATING PHYSIOLOGICALLY BASED PHARMACOKINETICS INTO CLINICAL CARE: REAL-WORLD PREDICTABILITY OF VALPROATE THERAPEUTIC DRUG MONITORING.
Favorite
PI-034
ONCOLOGIST CONSIDERATIONS WHEN CHOOSING BETWEEN 200 MG EVERY-3-WEEK VERSUS 400 MG EVERY-6-WEEK DOSING OF PEMBROLIZUMAB MONOTHERAPY WITHIN UPMC HILLMAN CANCER CENTER NETWORK
Favorite
PII-034
OPTIMIZING DOSE SELECTION FOR CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY IN THE TREATMENT OF PATIENTS WITH CANCER : A SYSTEMATIC REVIEW OF MECHANISTIC IN SILICO MODELS.
Favorite
PI-006
OPTIMIZING REGIMEN COMBINATIONS FOR TUBERCULOSIS DRUG DEVELOPMENT.
Favorite
PI-121
OPTIMIZING THE FIRST-IN-HUMAN STUDY DESIGN FOR BIOLOGICS EXHIBITING TARGET-MEDIATED DRUG DISPOSITION
Favorite
PI-107
OPTIMIZING VANCOMYCIN DOSING REGIMENS FOR OBESE PATIENTS
Favorite
P
PI-025
PATIENT PROFILES OF OPIOID USE DISORDER PATIENTS TREATED WITH ORAL VERSUS MONTHLY INJECTABLE BUPRENORPHINE USING U.S. REAL-WORLD MEDICAID CLAIMS DATA.
Favorite
PI-076
PATIENT-CENTRIC MICROSAMPLING VERSUS TRADITIONAL BLOOD SAMPLING: A PHARMACOKINETIC STUDY OF ZAVEGEPANT
Favorite
PII-023
PBPK MODEL DEVELOPMENT AND VALIDATION FOR ROSUVASTATIN: INTEGRATING IN VITRO, CLINICAL PHARMACOKINETIC, AND LIVER PET IMAGING DATA TO IMPROVE PREDICTIONS OF OATP1B- AND BCRP-MEDIATED DRUG-DRUG INTERACTIONS
Favorite
PI-098
PBPK MODEL REPRODUCIBILITY: LEARNINGS FROM THE DEVELOPMENT OF A PBPK MODEL REPOSITORY FOR GLOBAL HEALTH
Favorite
PII-099
PBPK MODELING TO PREDICT THE EFFECT OF GASTRIC PH ON BIOEQUIVALENCE OF PALBOCICLIB TABLETS
Favorite
PII-099
PBPK MODELING TO PREDICT THE EFFECT OF GASTRIC PH ON BIOEQUIVALENCE OF PALBOCICLIB TABLETS
Favorite
PI-099
PBPK MODELING TO SUPPORT THE EXPANSION OF BIOWAIVER TO NON-Q1/Q2 BCS CLASS III DRUG PRODUCTS.
Favorite
PI-113
PBPK-LED ASSESSMENT OF ANTIMALARIAL DRUG CONCENTRATIONS IN BREASTMILK: A STRATEGY FOR OPTIMAL USE OF PREDICTION METHODS TO GUIDE DECISION MAKING IN AN UNDERSTUDIED POPULATION
Favorite
PII-077
PHARMACODYNAMIC MODEL OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN PATIENTS WITH BREAST CANCER RECEIVING PACLITAXEL
Favorite
PII-006
PHARMACODYNAMIC MODELS AS EARLY PREDICTORS OF WEIGHT LOSS EFFICACY IN EARLY-PHASE CLINICAL RESEARCH
Favorite
PI-077
PHARMACOKINETIC ANALYSIS OF SEVASEMTEN IN A PHASE 1 STUDY IN HEALTHY SUBJECTS AND BECKER MUSCULAR DYSTROPHY PATIENTS
Favorite
PII-078
PHARMACOKINETIC BRIDGING OF JNJ-77242113 ORAL SOLUTION AND TABLET FORMULATIONS.
Favorite
PT-006
PHARMACOKINETIC DRUG-DRUG INTERACTION POTENTIAL OF ORAL ANTICANCER DRUGS.
Favorite
LB-013
PHARMACOKINETIC EVALUATION OF A NATURAL HEMP EXTRACT-BASED COSMETIC PRODUCT AFTER TOPICAL AND ORAL ADMINISTRATIONS.
Favorite
PI-078
PHARMACOKINETIC INTERACTION STUDIES OF COADMINISTRATION OF TAZEMETOSTAT WITH FLUCONAZOLE, REPAGLINIDE, OR OMEPRAZOLE IN PATIENTS WITH ADVANCED MALIGNANCIES.
Favorite
PII-121
PHARMACOKINETICS AND SAFETY OF NANOPARTICLE FENOFIBRATE (AD-104-A) IN RENAL IMPAIRMENT PATIENTS.
Favorite
PII-080
PHARMACOKINETICS OF A FULLY HUMAN BISPECIFIC PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) AND CLUSTER OF DIFFERENTIATION (CD3) BINDING MONOCLONAL ANTIBODY (AMG 340) IN SUBJECTS WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER
Favorite
PII-035
PHARMACOKINETICS OF AMG 193 (A SMALL MOLECULE MTA-COOPERATIVE PRMT5 INHIBITOR) AFTER SINGLE AND MULTIPLE DOSING IN THE FASTED AND FED IN STATE PATIENTS WITH MTAP DELETED TUMORS
Favorite
PI-079
PHARMACOKINETICS OF EDG-7500, A FIRST-IN-CLASS CARDIAC SARCOMERE MODULATOR FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
Favorite
PI-080
PHARMACOKINETICS OF NERANDOMILAST IN HEALTHY VOLUNTEERS
Favorite
PI-035
PHARMACOKINETICS OF TARLATAMAB, A DELTA LIKE LIGAND-3 (DLL3) TARGETED HALF-LIFE EXTENDED BISPECIFIC T-CELL ENGAGER (BITE) IMMUNOTHERAPY IN PATIENTS WITH PREVIOUSLY TREATED NEUROENDROCRINE PROSTATE CANCER (NEPC)
Favorite
PII-081
PHARMACOKINETICS OF THB001, AN ORALLY AVAILABLE, POTENT AND HIGHLY SELECTIVE SMALL MOLECULE INHIBITOR OF WILD TYPE KIT RECEPTOR TYROSINE KINASE, IN HEALTHY VOLUNTEERS
Favorite
PI-081
PHARMACOMETRIC MACHINE LEARNING: INTEGRATING NEURAL NETWORKS FOR FLEXIBLE, ADVANCED COVARIATE ANALYSIS
Favorite
PII-113
PHARMACOTHERAPY RESEARCH LANDSCAPE AND KNOWLEDGE GAP FOR OPIOIDS AMONG THE MATERNAL AND PEDIATRIC POPULATIONS
Favorite
PII-010
PHYSICIAN PERCEPTIONS ON ORAL HEALTH FOR PREGNANT WOMEN: BANGLADESH PERSPECTIVE
Favorite
PII-100
PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELLING FOR PREDICTING DRUG-DRUG INTERACTIONS (DDI) OF SHR2554
Favorite
PI-100
PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING TO CHARACTERIZE THE DISPOSITION OF TOPIRAMATE IN CHILDREN WITH AND WITHOUT OBESITY USING REAL-WORLD DATA.
Favorite
PII-101
PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL ANALYSIS OF ANTIPSYCHOTICS BEFORE AND AFTER CHILDBIRTH.
Favorite
TIP-003
PILOT STUDY ON VANCOMYCIN ADMINISTRATION VIA DIALYSATE IN PATIENTS RECEIVING CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT)
Favorite
TIP-003
PILOT STUDY ON VANCOMYCIN ADMINISTRATION VIA DIALYSATE IN PATIENTS RECEIVING CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT)
Favorite
PII-082
POPULATION EXPOSURE-RESPONSE ANALYSIS OF INOTUZUMAB OZOGAMICIN EFFICACY AND SAFETY IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA.
Favorite
PI-082
POPULATION PHARMACOKINETIC (PK)-PHARMACODYNAMIC (PD) MODELING OF ANUMIGILIMAB, A MONOCLONAL ANTIBODY THAT BLOCKS G-CSF BINDING TO THE G-CSF RECEPTOR
Favorite
PII-083
POPULATION PHARMACOKINETIC (POPPK) MODELING OF ENCORAFENIB (ENCO) IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH BRAF V600-MUTANT SOLID TUMORS IN PHASE 1, 2, AND 3 STUDIES: A SEMIMECHANISTIC AUTOINDUCTION MODEL.
Favorite
PI-083
POPULATION PHARMACOKINETIC ANALYSIS OF DUVAKITUG (TEV-48574) IN HEALTHY PARTICIPANTS AND PATIENTS WITH ASTHMA.
Favorite
PII-084
POPULATION PHARMACOKINETIC ANALYSIS OF MK-5475 IN HEALTHY PARTICIPANTS AND PATIENTS WITH PULMONARY HYPERTENSION
Favorite
PI-084
POPULATION PHARMACOKINETIC ANALYSIS OF SOTATERCEPT IN JAPANESE HEALTHY PARTICIPANTS AND JAPANESE PARTICIPANTS WITH PULMONARY ARTERIAL HYPERTENSION.
Favorite
PI-114
POPULATION PHARMACOKINETIC ANALYSIS TO OPTIMIZE THE DOSING REGIMEN OF 17-OHPC FOR PREVENTION OF PRETERM BIRTH
Favorite
PII-085
POPULATION PHARMACOKINETIC AND EXPOSURE-RESPONSE ANALYSIS OF ABATACEPT IN COVID-19 PATIENTS
Favorite
PI-085
POPULATION PHARMACOKINETIC MODEL OF TOTAL AND UNBOUND PAMIPARIB, A PARP INHIBITOR, IN GLIOBLASTOMA PATIENTS
Favorite
PII-086
POPULATION PHARMACOKINETIC MODELING OF FAMITINIB IN PATIENTS WITH VARIOUS CANCER TYPES INCLUDING METASTATIC CERVICAL CANCER
Favorite
PI-036
POPULATION PHARMACOKINETIC MODELING OF SUNITINIB AND SU12662 IN PATIENTS WITH SOLID TUMORS
Favorite
PI-086
POPULATION PHARMACOKINETIC OF BMS-986365, A DUAL ANDROGEN RECEPTOR (AR) LIGAND-DIRECTED DEGRADER AND ANTAGONIST, IN PATIENTS WITH PROGRESSIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Favorite
PII-087
POPULATION PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) MODELING OF DONIDALORSEN, AN ANTISENSE OLIGONUCLEOTIDE IN DEVELOPMENT FOR PROPHYLAXIS OF HEREDITARY ANGIOEDEMA.
Favorite
LB-014
POPULATION PHARMACOKINETICS AND BIOAVAILABILITY OF TACROLIMUS ORAL SUSPENSION IN CHILDREN WITH HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
Favorite
PI-087
POPULATION PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSIS FOR NTLA-2002 IN PATIENTS WITH HEREDITARY ANGIOEDEMA
Favorite
PII-088
POPULATION PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSIS FOR THE BIFUNCTIONAL PD-L1/TGF-βRII FUSION PROTEIN RETLIRAFUSP ALPHA TO SUPPORT A FLAT DOSE AS AN ALTERNATIVE REGIMEN
Favorite
PII-019
POPULATION PHARMACOKINETICS OF DELAMANID AND ITS METABOLITE DM-6705 IN MULTIDRUG-RESISTANT TUBERCULOSIS PATIENTS RECEIVING NOVEL SHORT-COURSE ORAL REGIMENS IN THE ENDTB AND ENDTB-Q TRIALS
Favorite
PI-088
POPULATION PHARMACOKINETICS OF ELEXACAFTOR, TEZACAFTOR AND IVACAFTOR IN REAL WORLD ADULT PATIENTS WITH CYSTIC FIBROSIS
Favorite
PII-089
POPULATION PHARMACOKINETICS OF ORAL MELTDOSE TACROLIMUS (LCPT) IN DE NOVO KIDNEY TRANSPLANT PATIENTS.
Favorite
PI-089
POPULATION PHARMACOKINETICS OF PYRAZINAMIDE FOR PATIENTS WITH MULTIDRUG RESISTANT TUBERCULOSIS
Favorite
LB-015
POPULATION PHARMACOKINETICS OF THE PARP INHIBITOR VELIPARIB IN PATIENTS WITH ADVANCED CANCER.
Favorite
PII-001
POPULATION PHARMACOKINETICS OF TRASTUZUMAB REZETECAN IN PATIENTS WITH HER2 EXPRESSING OR MUTATED ADVANCED MALIGNANT SOLID TUMORS
Favorite
PII-090
POPULATION PK (POPPK) AND EXPOSURE-SAFETY (E-S) ANALYSIS OF BT5528, A BICYCLE TOXIN CONJUGATE (BTC®), IN PATIENTS WITH ADVANCED SOLID TUMORS ASSOCIATED WITH EPHA2 EXPRESSION.
Favorite
PII-106
POPULATION PK AND PK/PD MODELING OF MARSTACIMAB, AN ANTI-TFPI MONOCLONAL ANTIBODY, IN ADULT AND ADOLESCENT HEMOPHILIA PATIENTS WITHOUT INHIBITORS
Favorite
PII-106
POPULATION PK AND PK/PD MODELING OF MARSTACIMAB, AN ANTI-TFPI MONOCLONAL ANTIBODY, IN ADULT AND ADOLESCENT HEMOPHILIA PATIENTS WITHOUT INHIBITORS
Favorite
PII-052
PRECISION MEDICINE IN PRACTICE: DEVELOPMENT OF AN AUTOMATED WARFARIN PHARMACOGENOMIC DOSING CALCULATOR EMBEDDED IN THE ELECTRONIC HEALTH RECORD.
Favorite
PII-036
PRECLINICAL TO CLINICAL TRANSLATION OF ADVERSE EVENTS FOR SMALL MOLECULE ONCOLOGY DRUGS
Favorite
PI-101
PREDICTING BRINZOLAMIDE OCULAR RESPONSE IN HUMANS USING AN OCULAR PBPK-PD MODELING AND SIMULATION
Favorite
PI-101
PREDICTING BRINZOLAMIDE OCULAR RESPONSE IN HUMANS USING AN OCULAR PBPK-PD MODELING AND SIMULATION
Favorite
PI-020
PREDICTING OPTIMAL PATIENT-CENTRIC TREATMENT DURATION FOR LEVOFLOXACIN-CONTAINING TUBERCULOSIS REGIMEN: AN INTEGRATED APPROACH OF A MODEL-BASED STRATIFICATION TOOL WITH SITE-OF-DISEASE PHARMACOLOGY KNOWLEDGE
Favorite
PII-102
PREDICTING THE EXPOSURE OF IRINOTECAN AND ITS ACTIVE METABOLITE (SN-38) IN CANCER PATIENTS USING PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING.
Favorite
PI-102
PREDICTION OF A CLAUDIN 18.2 TARGETED ANTIBODY DRUG CONJUGATE (ADC) PHARMACOKINETICS IN CANCER PATIENTS USING PBPK MODELING AND SIMULATION
Favorite
PII-124
PREDICTION OF CLINICAL OUTCOMES IN A HETEROGENOUS NSCLC VIRTUAL PATIENT POPULATION: A QUANTITATIVE SYSTEMS PHARMACOLOGY APPROACH.
Favorite
PI-024
PROMISING CAPACITY OF MACHINE LEARNING MODELS TO PREDICT OATP1B1- AND OATP1B3-MEDIATED INHIBITION POTENTIAL IN EARLY DRUG DISCOVERY.
Favorite
PI-090
PROTEIN BINDING: STATIC SOLUTIONS TO A DYNAMIC PROBLEM CAN BE MISLEADING IN DRUG DEVELOPMENT AND REGULATORY EVALUATION.
Favorite
PI-007
PROTEOMIC SIGNATURES IN THE CEREBROSPINAL FLUID (CSF) OF INDIVIDUALS WITH PRECLINICAL AND PRODROMAL ALZHEIMER'S DISEASE (AD): A KEY ROLE FOR ENDOTHELIAL AND ADHESION PROTEINS IN PRECLINICAL AD.
Favorite
PII-007
PYRIDOXIC ACID AS ENDOGENOUS BIOMARKER OF RENAL ORGANIC ANION TRANSPORTER ACTIVITY: POPULATION VARIABILITY AND MECHANISTIC MODELING TO PREDICT DRUG-DRUG INTERACTIONS
Favorite
Q
LB-016
QUANTIFYING HEART RATE CHANGES AFTER Δ-9-TETRAHYDROCANNABINOL (THC) ADMINISTRATION USING A PBPK-PD MODEL IN HEALTHY ADULTS
Favorite
PI-037
QUANTITATIVE CLINICAL PHARMACOLOGY SUPPORTS TOTALITY OF EVIDENCE, DATA INTEGRATION AND DOSE SELECTION PROPOSAL OF A NEW MOLECULAR ENTITY WITH NO SINGLE AGENT ACTIVITY DEVELOPED IN COMBINATION: CASE STUDY OF ENGLUMAFUSP ALFA
Favorite
PI-125
QUANTITATIVE SYSTEMS PHARMACOLOGY MODELING OF LONCASTUXIMAB TESIRINE-LPYL COMBINED WITH T CELL-DEPENDENT BISPECIFIC ANTIBODIES BRIDGES KNOWLEDGE AND DOSE REGIMEN STRATEGY FOR PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA
Favorite
PII-125
QUANTITATIVE SYSTEMS TOXICOLOGY (QST) MODELING USING BIOLOGXSYM AND MECHANISTIC TOXICITY DATA FROM A BIOMIMETIC LIVER MICROPHYSIOLOGY SYSTEM PREDICTS BIOLOGICS-INDUCED LIVER INJURY (BILI) FOR MULTIPLE LARGE MOLECULES.
Favorite
R
PII-037
REAL-WORLD CHARACTERIZATION OF DRUG-DRUG INTERACTIONS AMONG PATIENTS WITH ONCOGENE-DRIVEN NON-SMALL CELL LUNG CANCER USING TYROSINE KINASE INHIBITORS
Favorite
PT-008
REAL-WORLD CLINICAL OUTCOMES BY P2Y12 INHIBITOR THERAPY AND GENOTYPE IN BLACK VERSUS NON-BLACK PATIENTS FOLLOWING PCI.
Favorite
OAI-003
REAL-WORLD CLINICAL OUTCOMES BY P2Y12 INHIBITOR THERAPY AND GENOTYPE IN BLACK VERSUS NON-BLACK PATIENTS FOLLOWING PCI.
Favorite
E-002
REDUCTION IN ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) OBSERVED WITH DORAVIRINE (DOR) IS CAUSED BY INHIBITION OF ORGANIC CATION TRANSPORTER 2 (OCT2)
Favorite
PII-114
RELATIVE IMPACT OF CYP2D6 GENOTYPE PHENOTYPE ON EXPOSURE OF SSRIS DURING PREGNANCY: EXTRAPOLATION APPROACH USING RWD AND PBPK MODELLING
Favorite
PI-014
RESULTS OF A PHASE 1 CLINICAL TRIAL (GH001-HV-103) TO DETERMINE THE SAFETY AND TOLERABILITY OF MEBUFOTENIN (5-MEO-DMT), ADMINISTERED VIA INHALATION (GH001) IN HEALTHY SUBJECTS.
Favorite
PI-038
REVERSE-TRANSLATIONAL FINDINGS FOR DATOPOTAMAB DERUXTECAN (DATO-DXD) HUMAN EFFICACIOUS DOSE PREDICTION BASED ON MECHANISTIC PK/TUMOR GROWTH INHIBITION ANALYSIS FOR PATIENT-DERIVED AND CANCER CELL LINE-DERIVED XENOGRAFT MICE.
Favorite
S
PII-014
SAFETY , TOLERABILITY, AND PHARMACOKINETICS OF SM17 IN HEALTHY VOLUNTEERS, A NOVEL IL-17 RECEPTOR B TARGETING ANTIBODY IN PHASE I DEVELOPMENT FOR THE TREATMENT OF ASTHMA
Favorite
PI-106
SAFETY AND PHARMACOKINETICS OF DF-003, A TARGETED, FIRST-IN-CLASS ALPHA-KINASE 1 INHIBITOR FOR TREATMENT OF THE RARE GENETIC DISEASE, ROSAH SYNDROME.
Favorite
PII-091
SAFETY, PHARMACODYNAMICS, AND PHARMACOKINETICS OF IN-115314, A NOVEL SELECTIVE JAK1 INHIBITOR, AFTER A SINGLE OR MULTIPLE ORAL ADMINISTRATION IN HEALTHY MALE PARTICIPANTS.
Favorite
PI-016
SELTOREXANT DOES NOT PROLONG THE QT INTERVAL: A PLACEBO- AND POSITIVE-CONTROLLED, SINGLE DOSE PHASE 1 STUDY IN HEALTHY ADULTS
Favorite
PWI-002
SHORT-TERM PHARMACODYNAMIC EFFECTS OF CANAGLIFLOZIN IN HEALTHY AMISH VOLUNTEERS
Favorite
PT-009
SHORT-TERM PHARMACODYNAMIC EFFECTS OF CANAGLIFLOZIN IN HEALTHY AMISH VOLUNTEERS
Favorite
PII-020
SIMILAR BIOAVAILABILITY OF SUBCUTANEOUS BEPIROVIRSEN WHEN DELIVERED FROM A VIAL OR PREFILLED SYRINGE FITTED WITH A SAFETY SYRINGE DEVICE IN HEALTHY ADULT PARTICIPANTS
Favorite
PII-103
SPATIALCNS-PBPK: AN R/SHINY WEB-BASED PLATFORM FOR PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING OF SPATIAL PHARMACOKINETICS IN THE HUMAN CENTRAL NERVOUS SYSTEM AND BRAIN TUMORS
Favorite
PII-038
STRATEGIC CONSIDERATIONS FOR TUMOR DYNAMICS MODELING IN EARLY DEVELOPMENT: LEARNINGS FROM AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE
Favorite
PII-108
STREAMLINING POTENCY ASSESSMENT OF TOPICAL CORTICOSTEROIDS USING VASOCONSTRICTOR ASSAY (VCA)
Favorite
T
LB-005
TALAZOPARIB FORMULATION BRIDGING IN CANCER PATIENTS-CHALLENGES AND THE CRITICAL ROLE OF MIDD IN APPROVAL DESPITE FAILED BIOEQUIVALENCE
Favorite
PI-039
TARGETING OF CDK12/13 AND ANDROGEN PATHWAYS IN MESTASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Favorite
PI-091
THE DORSAL FOREARM AS A NOVEL TARGET FOR INTRAMUSCULAR INJECTIONS: CLINICAL PHARMACOKINETIC RESULTS.
Favorite
PII-039
THE EFFECT OF CARBAMAZEPINE ON THE PHARMACOKINETICS (PK) OF VEPDEGESTRANT, A PROTEOLYSIS TARGETING CHIMERA (PROTAC) ESTROGEN RECEPTOR (ER) DEGRADER IN HEALTHY ADULTS.
Favorite
PI-040
THE EFFECT OF DORDAVIPRONE (ONC201) ON CARDIAC REPOLARIZATION IN HEALTHY ADULT PARTICIPANTS
Favorite
PII-092
THE EFFECT OF POLYDRUG USE AND FENTANYL VACCINE ON THE PHARMACOKINETICS OF FENTANYL
Favorite
PI-021
THE EFFECTS OF OPIOIDS ON BLOOD-BRAIN BARRIER INTEGRITY, ANTIRETROVIRAL ACCUMULATION, AND NEUROINFLAMMATORY CHEMOKINE PROFILES IN ECOHIV-INFECTED MICE
Favorite
PII-040
THE IMPACT OF MILD, MODERATE AND SEVERE LIVER DYSFUNCTION ON THE PHARMACOKINETIC DISPOSITION OF MEZIGDOMIDE
Favorite
PI-115
THE MATERNAL AND PEDIATRIC PRECISION IN THERAPEUTIC (MPRINT) KNOWLEDGEBASE PORTAL: A POWERFUL INFRASTRUCTURE FOR MATERNAL AND PEDIATRIC PRECISION THERAPEUTICS RESEARCH
Favorite
PII-025
THE POTENTIAL OF SMARTWATCH-DERIVED CARDIAC MEASUREMENTS AS BIOMARKERS OF THERAPEUTIC RESPONSE IN CHILDREN WITH DISRUPTIVE BEHAVIOR DISORDER
Favorite
PI-092
THE SUPER APPROACH AS AN ALTERNATIVE FOR ESTIMATING THE PKPD PARAMETERS OF DRUGS IN COMBINATION THERAPIES
Favorite
LB-021
TRANSLATION OF RAT TO HUMAN BRAIN CONCENTRATIONS USING PBPK MODELING CONFIRMS HIGH BRAIN PENETRATION OF THE TYK2/JAK1 INHIBITOR BHV-8000.
Favorite
PII-093
TRANSLATIONAL MODELING OF BTZ-043 IN PREDICTING PHASE IIA EFFICACY AND EVALUATION OF DRUG-DRUG INTERACTIONS WITH BPAL IN MURINE MODELS
Favorite
PI-093
TRANSLATIONAL PHARMACOKINETIC/PHARMACODYNAMIC MODEL FOR NOVEL MRNA-MODALITY SUPPORTING ENZYME REPLACEMENT THERAPY.
Favorite
U
PII-094
UNRAVELING MOXIFLOXACIN'S BEHAVIOR IN NEXT-GENERATION TB REGIMENS.
Favorite
PI-008
USING BIOMARKERS TO PROVIDE EVIDENCE OF EFFECTIVENESS IN DRUG DEVELOPMENT FOR RARE DISEASES: SURVEY RESULTS FOR APPROVED ENZYME REPLACEMENT THERAPIES.
Favorite
PT-013
USING MODEL-BASED SIMULATIONS TO ALIGN MOUSE ANTIBIOTIC EXPOSURE WITH HUMAN CLINICAL EFFICACY FOR EXPLORATION OF COMBINATION THERAPY IN TUBERCULOSIS
Favorite
PI-103
UTILISING PHYSIOLOGICAL LYMPH FLOWS TO ENHANCE A MINIMAL PHYSIOLOGICALLY BASED PHARMACOKINETIC AND QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL FOR BIODISTRIBUTION OF MRNA ENCAPSULATED IN LIPID NANOPARTICLES WITH LIPID 5 IN RATS
Favorite
PT-001
UTILITY OF A PANEL OF ENDOGENOUS BIOMARKERS TO PREDICT DRUG-DRUG INTERACTIONS AND INTERINDIVIDUAL VARIABILITY INVOLVING ORGANIC ANION TRANSPORTERS 1 AND 3 ACTIVITY.
Favorite
PWII-001
UTILITY OF A PANEL OF ENDOGENOUS BIOMARKERS TO PREDICT DRUG-DRUG INTERACTIONS AND INTERINDIVIDUAL VARIABILITY INVOLVING ORGANIC ANION TRANSPORTERS 1 AND 3 ACTIVITY.
Favorite
PT-014
UTILIZING A DISEASE PROGRESSION MODEL TO DEVELOP A CLINICAL TRIAL SIMULATION TOOL THAT OPTIMIZES TRIAL DESIGN FOR AUTOSOMAL DOMINANT TUBULOINTERSTITIAL KIDNEY DISEASE.
Favorite
PII-104
UTILIZING A MINIMAL PBPK (MPBPK) MODEL TO PREDICT INTRA-TUMORAL CONCENTRATIONS OF MONOCLONAL ANTIBODIES.
Favorite
OAII-004
UTILIZING ADAPTIVE DOSING SIMULATIONS AND MACHINE LEARNING TO IMPROVE PREDICTION AND MANAGEMENT OF NEUTROPENIA RATES.
Favorite
PT-027
UTILIZING ADAPTIVE DOSING SIMULATIONS AND MACHINE LEARNING TO IMPROVE PREDICTION AND MANAGEMENT OF NEUTROPENIA RATES.
Favorite
V
PII-021
VIRAL VANGUARD: TURNING THE TIDE AGAINST SUPERBUGS
Favorite
W
PI-122
WHAT CAN WE LEARN FROM TRENDS IN PATIENT RECRUITMENT ADVERTISING IN THE PAST 20 YEARS?
Favorite
Y
OAI-001
YOURPGX ONCOLOGY: A NOVEL DIRECT-TO-PATIENT PORTAL FOR DELIVERING PHARMACOGENOMIC (PGX) RESULTS
Favorite
PT-010
YOURPGX ONCOLOGY: A NOVEL DIRECT-TO-PATIENT PORTAL FOR DELIVERING PHARMACOGENOMIC (PGX) RESULTS
Favorite
